<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02273531</url>
  </required_header>
  <id_info>
    <org_study_id>9.149</org_study_id>
    <nct_id>NCT02273531</nct_id>
  </id_info>
  <brief_title>Bioequivalence of a New Asasantin Formulation Extended Release (ER) Compared to the Commercially Available Asasantin Formulation (Aggrenox®; Extended Release) in Healthy Male and Female Volunteers</brief_title>
  <official_title>Bioequivalence of a New Asasantin Capsule Formulation (Extended Release Combination 200 mg Dipyridamole/25 mg ASA) Compared to the Commercially Available Asasantin Capsule Formulation (Aggrenox®; Extended Release Combination 200 mg Dipyridamole/25 mg ASA) Following Multiple Oral Administration at Steady State After a run-in Phase (Persantine ER BID for 2 Days Each: 25 mg, 50 mg, 100 mg, 150 mg [Persantine®]; 200 mg Dipyridamole/25 mg ASA [Asasantin ER])- an Open Label, Randomized, Multiple-dose, Two-way Crossover, Change-over Study in Healthy Male and Female Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to establish the bioequivalence of a new formulation of Asasantin ER compared to the
      present commercially available Asasantin ER formulation (Aggrenox®)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2004</start_date>
  <primary_completion_date type="Actual">March 2004</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the concentration-time curve of dipyridamole in plasma over one dosing interval at steady state (AUCτ,ss)</measure>
    <time_frame>up to 17 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum measured concentration of dipyridamole in plasma at steady state (Cmax,ss)</measure>
    <time_frame>up to 17 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimum measured concentration of dipyridamole in plasma at steady state (Cmin,ss)</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration of dipyridamole in plasma at steady state (Cavg)</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time from dosing to the maximum concentration of dipyridamole in plasma at steady state (tmax,ss)</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak trough fluctuation of dipyridamole in plasma (PTF)</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of the analytes that were eliminated in urine (Ae)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fraction in percent of dose of the analytes that was eliminated in urine (fe)</measure>
    <time_frame>up to 24 hours after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant changes in 12-lead ECG</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant changes in vital signs (blood pressure, pulse rate)</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with clinically significant changes in laboratory tests</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events</measure>
    <time_frame>up to 17 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of tolerability by the investigator on a 4-point scale</measure>
    <time_frame>after 17 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Asasantin ER, new formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Asasantin ER, present commercial formulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asasantin ER, new formulation</intervention_name>
    <arm_group_label>Asasantin ER, new formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Asasantin ER, present commercial formulation</intervention_name>
    <arm_group_label>Asasantin ER, present commercial formulation</arm_group_label>
    <other_name>Aggrenox®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Based upon a complete medical history, including the physical examination, vital signs
             (blood pressure (BP), pulse rate (PR)), 12-lead ECG, clinical laboratory tests:

               -  No finding deviating from normal and of clinical relevance

               -  No evidence of a clinically relevant concomitant disease

          -  Age ≥ 21 and ≤ 65 years

          -  Body mass index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2

          -  Signed and dated written informed consent prior to admission to the study in
             accordance with good clinical practice (GCP) and the local legislation

          -  Able to communicate well with the investigator and to comply with study requirements

        Exclusion Criteria:

          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,
             immunological or hormonal disorders

          -  Surgery of gastrointestinal tract (except appendectomy)

          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or
             neurological disorders

          -  History of relevant orthostatic hypotension, fainting spells or blackouts

          -  Chronic or relevant acute infections

          -  History of allergy/hypersensitivity (including drug allergy) which is deemed relevant
             to the trial as judged by the investigator

          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less
             than 10 half-lives of the respective drug prior to administration or during the trial

          -  Use of drugs which might reasonably influence the results of the trial based on the
             knowledge at the time of protocol preparation within 14 days prior to administration
             or during the trial

          -  Participation in another trial with an investigational drug within two months prior to
             administration or during the trial

          -  Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)

          -  Inability to refrain from smoking on trial days Alcohol abuse (more than 60 g/day)

          -  Drug abuse

          -  Blood donation (more than 100 mL within four weeks prior to administration or during
             the trial)

          -  Excessive physical activities (within one week prior to administration or during the
             trial)

          -  Any laboratory value outside the reference range that is of clinical relevance

          -  Inability to comply with dietary regimen of study centre

          -  History of frequent headaches

          -  History of gastro-intestinal ulcer disease

        For female subjects:

          -  Pregnancy

          -  Positive pregnancy test

          -  No adequate contraception e.g. oral contraceptives, sterilization, intrauterine device
             (IUD)

          -  Inability to maintain this adequate contraception during the whole study period

          -  Lactation period
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
  </link>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 23, 2014</study_first_submitted>
  <study_first_submitted_qc>October 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2014</study_first_posted>
  <last_update_submitted>October 23, 2014</last_update_submitted>
  <last_update_submitted_qc>October 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dipyridamole</mesh_term>
    <mesh_term>Aspirin, Dipyridamole Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

